MelanomaDB: A web tool for integrative analysis of melanoma genomic information to identify disease-associated molecular pathways

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Trevarton, Alexander J ^a   Mann, Michael B ^b   Knapp, Christoph ^a   Araki, Hiromitsu ^c   Wren, Jonathan D ^d,e   Stones Havas, Steven ^f   Black, Michael A ^g,h   Print, Cristin G ^a,h  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f Biomatters Ltd   (New Zealand)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h MAURICE WILKINS CENTRE FOR MOLECULAR BIODISCOVERY   (New Zealand)

Author keywords

BaseSpace; Gene set analysis; Melanoma; MelanomaDB; Molecular pathway; Mutation

Indexed keywords

BIOLOGICAL MARKER; DNA; RNA;

ARTICLE; CANCER GROWTH; CLINICAL ASSESSMENT TOOL; DISEASE SPECIFIC SURVIVAL; DNA SEQUENCE; DRUG EFFICACY; DRUGGABILITY INFORMATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOMICS; HUMAN; INFORMATION PROCESSING; INFORMATION SYSTEM; MELANOMA; MELANOMADB; MOLECULAR DYNAMICS; PUBLICATION; REFERENCE DATABASE; SCIENTIFIC LITERATURE; SIGNAL TRANSDUCTION; TUMOR GENE;

EID: 84883524470     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00184     Document Type: Article

References (85)

1. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res (2009) 37(Database issue):D885-90. doi:10.1093/nar/gkn764
2. Walia V, Mu EW, Lin JC, Samuels Y. Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 25(2):155-70. doi:10.1111/j.1755-148X.2012.00976.x
3. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2010) 463(7278):191-6. doi:10.1038/nature08658
4. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell (2012) 150(2):251-63. doi:10.1016/j.cell.2012.06.024
5. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 44(9):1006-14. doi:10.1038/ng.2359
6. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 485(7399):502-6. doi:10.1038/nature11071
7. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 9(2):166-80. doi:10.1593/neo.07112
8. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2011) 39(Database issue):D945-50. doi:10.1093/nar/gkq929
9. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 57:10.11.1-10.11.26. doi:10.1002/0471142905.hg1011s57
10. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 68(3):664-73. doi:10.1158/0008-5472.CAN-07-2615
11. Song S, Black MA. Microarray-based gene set analysis: a comparison of current methods. BMC Bioinformatics (2008) 9:502. doi:10.1186/1471-2105-9-502
12. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2012) 109(8):2724-9. doi:10.1073/pnas.1018854108
13. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 107(15):6994-9. doi:10.1073/pnas.0912708107
14. Obayashi T, Kinoshita K. Rank of correlation coefficient as a comparable measure for biological significance of gene coexpression. DNA Res (2009) 16(5):249-60. doi:10.1093/dnares/dsp016
15. Hatanaka Y, Nagasaki M, Yamaguchi R, Obayashi T, Numata K, Fujita A, et al. A novel strategy to search conserved transcription factor binding sites among coexpressing genes in human. Genome Inform (2008) 20:212-21. doi:10.1142/9781848163003_0018
16. Obayashi T, Kinoshita K. COXPRESdb: a database to compare gene coexpression in seven model animals. Nucleic Acids Res (2011) 39(Database issue):D1016-22. doi:10.1093/nar/gkq1147
17. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 64(15):5270-82. doi:10.1158/0008-5472.CAN-04-0731
18. Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, et al. Cell cycle gene networks are associated with melanoma prognosis. PLoS ONE (2012) 7(4):e34247. doi:10.1371/journal.pone.0034247
19. Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 22(23):2926-33. doi:10.1093/bioinformatics/btl483
20. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 4(1):44-57. doi:10.1038/nprot.2008.211
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 102(43):15545-50. doi:10.1073/pnas.0506580102
22. Araki H, Knapp C, Tsai P, Print C. GeneSetDB: a comprehensive meta-database, statistical and visualisation framework for gene set analysis. FEBS Open Bio (2012) 2:76-82. doi:10.1016/j.fob.2012.04.003
23. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 11(11):873-86. doi:10.1038/nrd3847
24. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 468(7326):973-7. doi:10.1038/nature09626
25. Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H, et al. HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res (2010) 38(Database issue):D665-9. doi:10.1093/nar/gkp945
26. Kaur M, Radovanovic A, Essack M, Schaefer U, Maqungo M, Kibler T, et al. Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res (2009) 37(Database issue):D820-3. doi:10.1093/nar/gkn593
27. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res (2012) 40(Database issue):D109-14. doi:10.1093/nar/gkr988
28. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic Acids Res (2011) 39(Database issue):D1035-41. doi:10.1093/nar/gkq1126
29. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2012) 40(Database issue):D1128-36. doi:10.1093/nar/gkr797
30. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 101(7):452-74. doi:10.1093/jnci/djp038
31. Schramm SJ, Mann GJ. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther (2011) 10(8):1520-8. doi:10.1158/1535-7163.MCT-10-0901
32. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol (2010) 2(2):125-48. doi:10.1177/1758834009360519
33. Blake PM, Decker DA, Glennon TM, Liang YM, Losko S, Navin N, et al. Toward an integrated knowledge environment to support modern oncology. Cancer J (2011) 17(4):257-63. doi:10.1097/PPO.0b013e31822c390b
34. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2012) 40(Database issue):D1100-7. doi:10.1093/nar/gkr777
35. Li Q, Lai L. Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics (2007) 8:353. doi:10.1186/1471-2105-8-353
36. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res (2012) 72(3):757-68. doi:10.1158/0008-5472.CAN-11-2781
37. UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res (2011) 39(Database issue):D214-9. doi:10.1093/nar/gkq1020
38. Chen Y, Zhang Y, Yin Y, Gao G, Li S, Jiang Y, et al. SPD-a web-based secreted protein database. Nucleic Acids Res (2005) 33(Database issue):D169-73. doi:10.1093/nar/gki093
39. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (2002) 298(5600):1912-34. doi:10.1126/science.1075762
40. Wren JD, Bekeredjian R, Stewart JA, Shohet RV, Garner HR. Knowledge discovery by automated identification and ranking of implicit relationships. Bioinformatics (2004) 20(3):389-98. doi:10.1093/bioinformatics/btg421
41. Wren JD. A global meta-analysis of microarray expression data to predict unknown gene functions and estimate the literature-data divide. Bioinformatics (2009) 25(13):1694-701. doi:10.1093/bioinformatics/btp290
42. Daum JR, Wren JD, Daniel JJ, Sivakumar S, McAvoy JN, Potapova TA, et al. Ska3 is required for spindle checkpoint silencing and the maintenance of chromosome cohesion in mitosis. Curr Biol (2009) 19(17):1467-72. doi:10.1016/j.cub.2009.07.017
43. Lupu C, Zhu H, Popescu NI, Wren JD, Lupu F. Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen. Blood (2011) 118(16):4463-71. doi:10.1182/blood-2011-05-355370
44. Clemmensen SN, Bohr CT, Rørvig S, Glenthøj A, Mora-Jensen H, Cramer EP, et al. Olfactomedin 4 defines a subset of human neutrophils. J Leukoc Biol (2012) 91(3):495-500. doi:10.1189/jlb.0811417
45. Towner RA, Jensen RL, Colman H, Vaillant B, Smith N, Casteel R, et al. ELTD1, a potential new biomarker for gliomas. Neurosurgery (2013) 72(1):77-90. discussion 91. doi:10.1227/NEU.0b013e318276b29d
46. John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 14(16):5173-80. doi:10.1158/1078-0432.CCR-07-4170
47. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med (2006) 4:50. doi:10.1186/1479-5876-4-50
48. Journe F, Id Boufker H, Van Kempen L, Galibert MD, Wiedig M, Salès F, et al. TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. Br J Cancer (2011) 105(11):1726-32. doi:10.1038/bjc.2011.451
49. Timar J, Gyorffy B, Raso E. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis (2010) 27(6):371-87. doi:10.1007/s10585-010-9307-2
50. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 106(48):20429-34. doi:10.1073/pnas.0905139106
51. Jönsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringnér M, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 16(13):3356-67. doi:10.1158/1078-0432.CCR-09-2509
52. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 19(2):185-93. doi:10.1093/bioinformatics/19.2.185
53. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, et al. Integrative analysis of the melanoma transcriptome. Genome Res (2010) 20(4):413-27. doi:10.1101/gr.103697.109
54. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2012) 44(2):133-9. doi:10.1038/ng.1026
55. Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 41(5):518-20. doi:10.1038/ng.340
56. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 41(10):1127-32. doi:10.1038/ng.438
57. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 43(11):1119-26. doi:10.1038/ng.950
58. Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet (2012) 44(2):165-9. doi:10.1038/ng.1041
59. Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2012) 22(2):196-207. doi:10.1101/gr.125591.111
60. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 43(5):442-6. doi:10.1038/ng.810
61. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 483(7391):603-7. doi:10.1038/nature11003
62. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol (1995) 57(1):289-300.
63. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 20(9):1297-303. doi:10.1101/gr.107524.110
64. Sales G, Calura E, Cavalieri D, Romualdi C. graphite-a Bioconductor package to convert pathway topology to gene network. BMC Bioinformatics (2012) 13:20. doi:10.1186/1471-2105-13-20
65. Warnes G. Gtools: Various R Programming Tools. R Package 2.7.0. (2012).
66. Kelleher FC, McArthur GA. Targeting NRAS in melanoma. Cancer J (2012) 18(2):132-6. doi:10.1097/PPO.0b013e31824ba4df
67. Jensen TO, Hoyer M, Schmidt H, Moller HJ, Steiniche T. The prognostic role of protumoral macrophages in AJCC stage I/II melanoma [abstract]. J Clin Oncol (2008) 26(15S):9017.
68. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 29(41):5545-55. doi:10.1038/onc.2010.323
69. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS ONE (2012) 7(1):e29336. doi:10.1371/journal.pone.0029336
70. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 31(13):3812-4. doi:10.1093/nar/gkg509
71. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods (2010) 7(4):248-9. doi:10.1038/nmeth0410-248
72. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE (2012) 7(10):e46688. doi:10.1371/journal.pone.0046688
73. ENCODE Project Consortium, Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, et al. An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 489(7414):57-74. doi:10.1038/nature11247
74. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res (2012) 22(9):1775-89. doi:10.1101/gr.132159.111
75. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res (2011) 71(11):3852-62. doi:10.1158/0008-5472.CAN-10-4460
76. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature (2012) 489(7414):109-13. doi:10.1038/nature11279
77. de Graaf CA, van Steensel B. Chromatin organization: form to function. Curr Opin Genet Dev (2012) 23(2):185-90. doi:10.1016/j.gde.2012.11.011
78. Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 8:56. doi:10.1186/1479-5876-8-56
79. Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, et al. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol (2010) 223(2):352-8. doi:10.1002/jcp.22040
80. Howell PM Jr., Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control (2009) 16(3):200-18.
81. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 12(4):R41. doi:10.1186/gb-2011-12-4-r41
82. Sanchez-Garcia F, Akavia UD, Mozes E, Pe'er D. JISTIC: identification of significant targets in cancer. BMC Bioinformatics (2010) 11:189. doi:10.1186/1471-2105-11-189
83. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An integrated approach to uncover drivers of cancer. Cell (2010) 143(6):1005-17. doi:10.1016/j.cell.2010.11.013
84. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 12(5):349-61. doi:10.1038/nrc3218
85. Utikal J, Schadendorf D, Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res (2007) 298(10):469-77.